Brodalumab established as an effective interleukin-17 receptor antagonist in psoriasis
- PMID: 27535597
- DOI: 10.1111/bjd.14728
Brodalumab established as an effective interleukin-17 receptor antagonist in psoriasis
Comment on
-
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.Br J Dermatol. 2016 Aug;175(2):273-86. doi: 10.1111/bjd.14493. Epub 2016 Jun 23. Br J Dermatol. 2016. PMID: 26914406 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical